DRIO$10.26
Chart
Performance
Key Stats
AI DRIO Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldDarioHealth shows potential in the digital health sector but faces significant financial headwinds and negative momentum. Further analysis needed to confirm sustainable recovery.
Thematic
DarioHealth operates in the growing digital therapeutics market, addressing chronic conditions and behavioral health, which are strong secular trends. However, competition and adoption rates remain key factors.
Fundamental
DarioHealth exhibits significant negative profitability and cash burn. While revenue has shown some growth, high operating expenses and substantial net losses present substantial financial risk.
Technical
The stock is experiencing a significant downward trend across multiple timeframes, with price below key moving averages and weak momentum indicators.
| Factor | Score |
|---|---|
| Digital Health Adoption | 80 |
| Chronic Disease Management | 75 |
| Behavioral Health Integration | 65 |
| Market Competition | 50 |
| Regulatory Landscape | 60 |
| Factor | Score |
|---|---|
| Valuation | 50 |
| Profitability | 5 |
| Growth | 70 |
| Balance Sheet Health | 55 |
| Cash Flow | 10 |
| Factor | Score |
|---|---|
| Trend Analysis | 20 |
| Momentum | 30 |
| On-Balance Volume (OBV) | 25 |
| Support & Resistance | 40 |
| Short-term Performance | 20 |
AI Investing Checklist
Powered by LiveAIBullish Points (5)
Attractive Valuation vs. Growth
The stock's Price/Earnings to Growth (PEG) Ratio is 0.95, a value under 1.0 that can indicate its price is undervalued relative to its expected earnings growth. The trailing Price-to-Sales (P/S) ratio is 1.4, which is relatively low given the company's revenue of $21.78M.
Solid Liquidity Position
The company maintains a strong Current Ratio of 2.43 (Current Assets $40.5M / Current Liabilities $16.6M), indicating a solid ability to meet short-term obligations. The company has $27.76M in cash and equivalents with a market cap of $31.12M.
Bearish Points (6)
Consistent Net Losses
The company has consistently reported net losses over the past few years, with a net income of -$42.75M in 2024 and -$59.43M in 2023. EPS estimates have also been negative for the recent quarters.
Negative Net Margin
Net margins have been significantly negative, indicating that the company's expenses exceed its revenues. The net margin for 2024 was -158.1%, and for 2023 it was -292.0%.
Calendar
November 2019
18
Next Dividend Date
August 2025
14
Next Earnings Date
H: $-0.09
A: $-0.10
L: $-0.12
H: 7.00M
A: 6.91M
L: 6.80M
Profile
DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Connect, a solution used to create communities around specific health conditions to increase awareness and education; Dario Mind, a behavioral health offering that decreases the symptoms of stress, anxiety, and depression; Dario Move, focuses on improving posture to alleviate pain with medical device; and Dario Health, a self-care application and virtual coaching platform for diabetes, hypertension, and weight management and GLP-1. It also provides bundled full-suite or partial-suite subscriptions. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.
Seasonals
Price Target
2.38 USD
The 39 analysts offering 1 year price forecasts for DRIO have a max estimate of 4.00 and a min estimate of 1.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
Direct competitor in virtual care and chronic condition management (diabetes, hypertension, weight) through its integrated platforms.
Weight: 95
Leading manufacturer of Continuous Glucose Monitoring (CGM) systems, a core technology that DRIO's diabetes management platform integrates with and leverages.
Weight: 92
Maker of the Freestyle Libre CGM and other significant medical devices for diabetes management, directly competing with or complementing DRIO's focus.
Weight: 88
Known for sleep apnea devices, but with a substantial digital health arm (e.g., Propeller Health) and a focus on remote patient monitoring and chronic disease management.